No Data
Cutia Therapeutics' Phase 2 Trial of Drug for Adipose Accumulation-Related Diseases Complete Database Lock
Kede Bi-B (02487.HK): The revenue from commercialized products in the first three quarters increased by 129.9% year-on-year.
KeDi-B (02487.HK) announced on October 31 that as of the nine months ending September 30, 2024, the group's commercialized product revenue was approximately RMB 0.1489 billion, recording a positive growth of about 129.9% compared to the same period in 2023.
Express News | Cutia Therapeutics - 9M Revenue of Group's Commercialized Products RMB148.9 Mln
Express News | Cutia Therapeutics - CEO Purchased Total of 8,000 Shares on 9 and 10 October for HK$102,816
Consumer Electronics - B (02487.HK) spent 0.2562 million Hong Kong dollars on repurchasing 0.0188 million shares on October 8th.
Gelonghui October 9th | Ke Di - B (02487.HK) announced that on October 8, 2024, it spent 0.2562 million Hong Kong dollars to repurchase 0.0188 million shares at a repurchase price of 12.32-15.18 Hong Kong dollars per share.
Cutia Therapeutics CFO Purchases Shares; Shares Plummet 21%
No Data
No Data